| Identification | Back Directory | [Name]
IOXILAN (400 MG) | [CAS]
107793-72-6 | [Synonyms]
Ioxitol
Oxilan 300
IOXILAN (400 MG)
5-[Acetyl(2,3-dihydroxypropyl)aMino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- | [Molecular Formula]
C18H24I3N3O8 | [MDL Number]
MFCD00867280 | [MOL File]
107793-72-6.mol | [Molecular Weight]
791.11 |
| Chemical Properties | Back Directory | [Boiling point ]
827.8±65.0 °C(Predicted) | [density ]
2.205±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 250 mg/mL (316.01 mM) | [form ]
Solid | [pka]
11.47±0.46(Predicted) | [color ]
White to off-white | [Major Application]
pharmaceutical (small molecule) | [InChI]
1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) | [InChIKey]
UUMLTINZBQPNGF-UHFFFAOYSA-N | [SMILES]
Ic1c(c(c(c(c1C(=O)NCC(O)CO)I)C(=O)NCCO)I)N(CC(O)CO)C(=O)C | [EPA Substance Registry System]
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6) |
| Hazard Information | Back Directory | [Uses]
Nonionic iodinated contrast medium. Diagnostic aid (radiopaque medium). | [Definition]
ChEBI: Ioxilan is an amidobenzoic acid. | [Brand name]
Oxilan (Guerbet). | [in vivo]
Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region[1]. |
|
| Company Name: |
Spectrum Chemical Manufacturing Corp.
|
| Tel: |
021-021-021-67601398-809-809-809 15221380277 |
| Website: |
www.spectrumchemical.com/oa_html/index.jsp?minisite=10020&respid=22372&language=us |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|